HIV

Many people at high risk of getting HIV—including those who inject drugs, gay and bisexual men, and partners of people with HIV—are not screened annually and experience delays in diagnosis.

For people living with HIV who achieve viral suppression from antiretroviral therapy, there is a reduced risk of developing both AIDS-defining cancer and non-AIDS-defining cancer.

On National HIV Testing Day on June 27, Walgreens and Greater Than AIDS will partner with over 200 health and community organizations to provide free HIV testing and information at Walgreens stores in over 180 cities.

The 70 National Cancer Institute (NCI)-designated cancer centers underscored the importance of increased HPV vaccination and evidence-based screening, with the goal of eliminating cancers caused by the human papillomavirus (HPV).

New study results have concluded that antiretroviral therapy (ART) initiation within 30 days of HIV diagnosis is associated with a significantly reduced risk of treatment dropout and failure.

Among HIV-positive women with diabetes, HIV control has improved over time, but diabetes control has not.

As this month marks the 15th anniversary, the US President’s Emergency Plan for AIDS Relief (PEPFAR) now supports over 14 million people globally with HIV treatment.

The HOPE in Action Multicenter Kidney Study will examine the safety of HIV-to-HIV kidney transplantation.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care stories include the finding that new guidelines will mean the number of people with hypertension will soar; research finds that most diabetes apps don’t lower glycated hemoglobin; and a health plan announced its plan to fight housing instability.

Neurological damage begins early in infection, particularly during untreated infection, and worsens with the continued absence of combination antiretroviral therapy (cART). However, initiating cART may halt further deterioration, emphasizing the importance of early cART.

The FDA has warned of serious cases of neural tube birth defects involving the brain, spine, and spinal cord affecting babies born to women with HIV being treated with dolutegravir.

The FDA has approved an expanded indication for Gilead Science’s emtricitabine/tenofovir disoproxil fumarate (Truvada) to reduce the risk of HIV in at-risk adolescents. Truvada for pre-exposure prophylaxis (PrEP) was first approved for the use in adults in 2012.

The FDA has drafted new recommendations on the development of drugs to treat pediatric patients with HIV meant to be applied on a global scale.

Through an HIV heatmap, as well as an extensive survey and customized web-based software to connect social determinants with viral suppression rates, an HIV primary care program is working to reduce the number of new HIV diagnoses and increase viral suppression rates in Long Island and Queens.

The total cancer burden among people living with HIV will decrease from 8150 cases in 2010 to 6690 cases in 2030, and prostate and lung cancers will emerge as the most common types of cancer facing the patient population.

Aimee Tharaldson, PharmD, a senior clinical consultant in Emerging Therapeutics for Express Scripts, discusses specialty drugs that have recently been approved, and which we will likely see approved in the remainder of the year.

Tahir Amin, DipLP, co-founder and co-executive director of the Initiative for Medicines, Access, and Knowledge, discusses the organization’s focus on patent opposition for HIV drugs, the results of their work, and what efforts are still needed.

Patients with gaps between HIV primary care visits of 6 months up until 9 months did not have a significant difference in viral suppression loads. However, with gaps of 12 months or more, 23% of patients became unsuppressed.

Researchers from the University of Massachusetts Medical School will test the safety and tolerability of a vaccine that may have the potential to prevent HIV infection.

Between 2000 and 2015, $562.6 billion was spent on HIV/AIDS, with most spending occurring in high-income and upper-income countries and out-of-pocket spending accounting for less than 10%, according to the first long-term, comprehensive analysis of funding for the disease.

At the Academy of Managed Care Pharmacy's Managed Care & Specialty Pharmacy Annual Meeting, held April 23-26, in Boston, Massachusetts, an overflow capacity crowd gathered for one of the meeting’s yearly highlights­: Specialty Pharmaceuticals in Development. Aimee Tharaldson, PharmD, a senior clinical consultant in Emerging Therapeutics for Express Scripts, talked about the key trends in the specialty drug market, including cancer drugs, new competition, and orphan drugs.

A panel of experts in infectious disease and managed care to discuss management of HIV, including the need for individualized care and the role for newer treatments options.

AIDSinfo, a portal from the National Institutes of Health, has outlined recent changes that have been made to the adult, adolescent, and perinatal HIV guidelines, including the incorporation of people-first language.